TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00725725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
Study: NCT01672307
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is applied twice daily to the other eyebrow.
Study: NCT01829295
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
Study: NCT04571515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT04721912
Drug: Probiotic dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBS positive patients, at ≥ 36 weeks gestation, will begin taking oral Florajen Digestion probiotic capsules once daily from time of enrollment/randomization at ≥ 36 weeks gestation until the time of birth.
Study: NCT03829410
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI intravenously.
Study: NCT05154201
Drug: ORIN1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation of ORIN1001 as a single agent or in combination with standard of care. Dose expansion of ORIN1001 as a single agent or in combination with standard of care.
Study: NCT01086410
Drug: Placebo Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
Study: NCT01086410
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo capsule taken each day on the last 7 days of the study
Study: NCT01086410
Drug: Prednisolone Oral Capsule
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
Study: NCT03749525
Drug: shenfu injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: we hypothesis that shenfu injection could improve patients' arterial vascular reactivity with septic shock
Study: NCT02105766
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Immunosuppressant
Study: NCT04030039
Drug: nucleoside analogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: chronic hepatitis B patients with interferon therapy
Study: NCT01971502
Drug: Placebo to BI 1060469
Approvals — FDA: no, EMA: no, PMDA: no
Description: single rising doses
Study: NCT00515255
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsules
Study: NCT03034460
Drug: CD5024 1% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 µL on half-face, five days a week during 6 weeks
Study: NCT03034460
Drug: CD0271/CD1579 gel placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 µL on half-face, five days a week during 6 weeks
Study: NCT03701399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04086745
Drug: TNF Inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04556838
Drug: VVN001 Ophthalmic Solution 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: VVN001 Ophthalmic Solution 1%
Study: NCT04556838
Drug: VVN001 Ophthalmic Solution 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: VVN001 Ophthalmic Solution 5%
Study: NCT04556838
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: VVN001 Ophthalmic Solution Vehicle
Study: NCT00995930
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACZ885 150 mg was administered subcutaneously once a month for 12 months.
Study: NCT03516838
Drug: ACTIVA™ BioACTIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restorative Dental Material: Permanent resin containing filling dental material with bioactive properties to restore decayed teeth
Study: NCT03516838
Drug: Compomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restorative Dental Material: Permanent resin containing filling dental material to restore decayed teeth
Study: NCT03642665
Drug: Natural cycle
Normalized name: Natural Cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: no medication
Study: NCT03505320
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin will be administered as a 2-hour IV infusion.
Study: NCT03505320
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil will be administered as IV bolus over 5 to 15 minutes and continuous IV infusion over 46 to 48 hours or per institutional guidelines.
Study: NCT03959085
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03959085
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03959085
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO or IV
Study: NCT03959085
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03959085
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT or IV
Study: NCT03959085
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT01799213
Drug: Meloxicam 15 mg po QD
Normalized name: meloxicam 15 MG
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible subjects will be take Meloxicam 15 mg po QD
Study: NCT00554788
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04437511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03355469
Drug: Low Intensity Exercise + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Intensity exercise (LoEx) measured by a percentage of maximal heart rate in combination with placebo.
Study: NCT03355469
Drug: High Intensity Exercise + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Intensity exercise (HiEx) measured by a percentage of maximal heart rate in combination with placebo.
Study: NCT01585831
Drug: Testosterone gel 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist after reviewing labs.
Study: NCT01585831
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist.
Study: NCT04768023
Drug: Juvit D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage based on the BMI as followed: for BMI under 25 - 4000 IU/day, for BMI between 25 and 30 - 5000 IU/day, and for BMI over 30 - 6000 IU/day.
Study: NCT04768023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching amount of vegetable oil to the vitamin D3.
Study: NCT00259779
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01698281
Drug: AEZS-108
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEZS-108 (267 mg/m2, 2-hour IV infusion every Day 1 of a 21-day (3-week) cycle. Allowed delay of re-treatment: up to 2 weeks.~Dose reduction: to 210 mg/m2 and 160 mg/m2, if dose limiting toxicity.
Study: NCT00857532
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
Study: NCT04367883
Drug: ACEI
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention is performed. We propose an observational study.
Study: NCT04367883
Drug: ARB
Normalized name: Arbli
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention is performed. We propose an observational study.
Study: NCT01205438
Drug: LY2127399
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
Study: NCT01205438
Drug: Placebo every 2 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
Study: NCT01205438
Drug: Placebo every 4 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via subcutaneous injection for 52 weeks.
Study: NCT00346099
Drug: Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00346099
Drug: Panitumumab with capecitabine and radiation
Normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05053477
Drug: mehylprednisolone injection
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (40 mg)
Study: NCT03632109
Drug: gentamicin 360mg IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360mg IM of gentamicin
Study: NCT00828373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
Study: NCT02623426
Drug: Intravitreal Methotrexate 400 µg
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
Study: NCT03490162
Drug: DM1157
Approvals — FDA: no, EMA: no, PMDA: no
Description: DM1157 is a novel anti-malarial drug that is derived from chloroquine. DM1157 maintains the efficacy of chloroquine and has molecular features that overcome resistance to chloroquine.
Study: NCT02630199
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
Study: NCT01233869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral dose of placebo
Study: NCT01245634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv infusion every 4 weeks, 32 weeks
Study: NCT01245634
Drug: RO4905417
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg iv infusion every 4 weeks, 32 weeks
Study: NCT00650065
Drug: Zyrtec® Tablets 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg, single dose fasting
Study: NCT04123483
Drug: EnBrace HR Softgel
Normalized name: EnBrace HR Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 8 week study
Study: NCT02953132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02676856
Drug: Conditioning for CR group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
Study: NCT02676856
Drug: Conditioning for Non-CR group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
Study: NCT05829707
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A group of patients with breast cancer who were randomized to the diclofenac group by drawing random numbers was given 2 x 75 mg of drug IV on the first PO day and then 3 x 50 mg tablets orally for postoperative analgesia.~All patients were assessed before the surgical procedure: hand grip strength, shoulder disability, and health-related quality of life were measured. Pain relief was assessed by the visual analog scale (VAS) from 0-10.~Rescue analgesia was offered for pain \>4 on the VAS, meperidine 20-30 mg for VAS \>or = 4
Study: NCT00528567
Drug: Standard adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
Study: NCT02754765
Drug: Control arm MDR-TB regimen, consistent with WHO guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm MDR-TB regimen, consistent WHO guidelines
Study: NCT01963793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel without active component
Study: NCT00916201
Drug: URB597
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg / d for 5 days, orally
Study: NCT02521831
Drug: Spinal Anesthesia (bupivacaine)
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine is an amide-type, long-acting local anesthetic. Brand names include Exparel, Marcaine, and Sensorcaine.
Study: NCT00912444
Drug: Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
Study: NCT00912444
Drug: Docetaxel, cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
Study: NCT02496572
Drug: Short course MDR-TB treatment regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive phase:~Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.~Continuation phase:~Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration.
Study: NCT04552262
Drug: BAY2327949
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 90 mg BAY2327949
Study: NCT04552262
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo to BAY 2327949
Study: NCT03484260
Drug: Testosterone Product
Normalized name: testosterone Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Men used testosterone product following prescription
Study: NCT03762915
Drug: minocycline HCl microspheres
Normalized name: minocycline HCl microspheres
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline HCl microspheres, 1 mg are approved by the Food and Drug Administration (FDA) as an adjunct to SRP procedures for reduction of pocket depth in patients with adult periodontitis.
Study: NCT04645550
Drug: Low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
Study: NCT01219959
Drug: Dianeal
Normalized name: Dianeal PD-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
Study: NCT01219959
Drug: Dianeal, Extraneal, Nutrineal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
Study: NCT04682431
Drug: PY159 Single agent dose level 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of PY159 as a single agent given in a standard 3+3 design.
Study: NCT04682431
Drug: PY159 Single agent dose expansion cohort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of PY159 as a single agent given for predefined tumor histology
Study: NCT01665573
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acquisition of conditioning Administration of placebo Extinction of conditioning
Study: NCT00276731
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03206671
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: see detailed protocol description
Study: NCT04715386
Drug: StrataXRT
Normalized name: Strataxrt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be asked to start topical application of their allocated topical preparation on the area of skin that will be irradiated at the onset of radiation therapy, every day until skin symptoms subside (see patient information pamphlet). Apply twice per day and can be reapplied as skin symptoms arise or as needed. The amount of StrataXRT provided to each patient will be recorded throughout treatment.
Study: NCT01678924
Drug: AGN-214868
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-214868 given as injections into the area of pain on Day 1.
Study: NCT03206671
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see detailed protocol description
Study: NCT03206671
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: see detailed protocol description
Study: NCT03206671
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see detailed protocol description
Study: NCT03232749
Drug: corticosteroid injections
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid will be administered is used to treat pain and swelling that occurs with arthritis and other joint disorder
Study: NCT03844620
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by mouth
Study: NCT02433535
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.
Study: NCT03232905
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as tablet
Study: NCT02056574
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01566474
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
Study: NCT02156466
Drug: MSB0010841
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Study: NCT02156466
Drug: MSB0010841
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Study: NCT02156466
Drug: MSB0010841
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Study: NCT02156466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
Study: NCT00881621
Drug: Lapatinib and Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
Study: NCT03151967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal applicator with medium containing no drug
Study: NCT01706679
Drug: Placebo vehicle (PBS)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01858558
Drug: No aMIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
Study: NCT04090684
Drug: Fixed dose combination Ciprofloxacin/Celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day
Study: NCT00293475
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IA
Study: NCT02010970
Drug: Group 1 AZD3293
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3293 oral solution
Study: NCT02010970
Drug: Group 2 AZD3293
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3293 oral solution
Study: NCT02010970
Drug: Group 3 AZD3293
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3293 oral solution
Study: NCT04250311
Drug: MMH-407
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMH-407: For oral use.
Study: NCT04250311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: For oral use.
Study: NCT00546832
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02737436
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning